Wolfe Research Initiates Coverage On Alnylam Pharmaceuticals with Peer Perform Rating
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Andy Chen initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Peer Perform rating, indicating a neutral outlook on the company's stock.

February 15, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wolfe Research initiated coverage on Alnylam Pharmaceuticals with a Peer Perform rating, suggesting a neutral stance on the company's future stock performance.
The initiation of coverage by Wolfe Research with a Peer Perform rating typically indicates a neutral perspective on the stock's short-term price movement. Given the influence of analyst ratings on investor sentiment, this could stabilize the stock price, but it's unlikely to cause significant short-term fluctuations.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90